TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results, Misses Expectations By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) posted its quarterly earnings results on Friday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports.

TuHURA Biosciences Price Performance

Shares of TuHURA Biosciences stock traded down $0.20 on Friday, hitting $2.31. The company had a trading volume of 613,892 shares, compared to its average volume of 817,524. The firm has a market capitalization of $147.11 million, a P/E ratio of -3.79 and a beta of -0.01. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.05. The stock has a 50-day moving average of $2.14 and a 200-day moving average of $1.61.

Analyst Ratings Changes

HURA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target for the company. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Citigroup assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after buying an additional 35,426 shares during the period. Geode Capital Management LLC boosted its holdings in shares of TuHURA Biosciences by 6.4% in the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after buying an additional 39,710 shares during the period. State Street Corp boosted its holdings in shares of TuHURA Biosciences by 4.9% in the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after buying an additional 13,594 shares during the period. Deutsche Bank AG boosted its holdings in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares during the period. Finally, Barclays PLC boosted its holdings in shares of TuHURA Biosciences by 42.6% in the fourth quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after buying an additional 15,725 shares during the period. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.